Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Lung Cancer

LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Status Conditions Phase Study ID
Closed Tumors Characterized by Genetic Abnormalities of ALK Phase I (UW10038)
NCT01283516
Summary

This study will assess the safety and early efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).


Investigator
Laura Chow, MD
Location    
SCCA Phase 1 Program Office 206-288-7551 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)

 

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Tumor must be confirmed to be ALK positive

Exclusion Criteria:

  • Pregnant
  • Active pancreatitis
  • Active or chronic liver disease

Other protocol-defined inclusion/exclusion criteria may apply

Last Updated
August 23, 2013
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.